NHG advised the Corporación Andina de Fomento on a Private Equity deal

NHG advised the Corporación Andina de Fomento (CAF) on the equity investment of Patia Biopharma, for the development of a cost-efficient genetic test to identify high-risk patients of diabetes that may get SARS-Cov-2 in order to adopt precautionary measures, through the run of tests and samples compilations in Spain, Mexico and Peru.